ProQR Therapeutics N.V.（PRQR）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · PRQR · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2025-12	2024-12	2023-12	2022-12	2021-12
Revenue
Revenue	$15.28M	$18.91M	$6.51M	$3.59M	$1.33M
Cost of Revenue	$2.60M	$0.00M	$0.00M	$0.00M	$0.00M
Gross Profit	$12.68M	$18.91M	$6.51M	$3.59M	$1.33M
Gross Margin %(computed)	83.01%	100.00%	100.00%	100.00%	100.00%
Operating Expenses
R&D Expenses	$40.72M	$36.36M	$25.15M	$50.87M	$42.22M
G&A Expenses	$0.00M	$13.66M	$16.24M	$18.65M	$17.37M
Total Operating Expenses	$54.84M	$49.38M	$38.37M	$68.75M	$58.55M
Operating Income	($42.15M)	($30.47M)	($31.86M)	($65.16M)	($57.21M)
Operating Margin %(computed)	-275.91%	-161.18%	-489.09%	—	—
Interest Income	$2.24M	$3.25M	$2.59M	$0.11M	$0.01M
Interest Expense	$0.87M	$1.08M	$1.20M	$5.13M	$3.40M
Income Before Tax	($40.50M)	($27.96M)	($27.81M)	($64.11M)	($60.68M)
Income Tax Expense	$0.02M	($0.20M)	($0.08M)	$0.10M	$0.12M
Net Income	($40.52M)	($27.76M)	($28.12M)	($64.42M)	($60.74M)
Net Margin %(computed)	-265.21%	-146.86%	-431.67%	—	—
Per Share & EBITDA
EPS (Basic)	$-0.38	$-0.34	$-0.35	$-0.91	$-0.96
Wtd Avg Shares	105.33M	81.67M	81.01M	71.64M	64.18M
EBITDA	($39.56M)	($24.12M)	($24.10M)	($56.46M)	($54.95M)
EBITDA Margin %(computed)	-258.92%	-127.60%	-369.93%	—	—